Posts Tagged: GSK
I’m not defending what Novartis did or trying to find an excuse for the company. It violated the FCPA, and (along with a former subsidiary) paid nearly $347 million in penalties and disgorgement to resolve the offenses.… Continue Reading
China has been mentioned in more than 60 FCPA corporate enforcement actions, including eight in 2019 alone. So FCPA practitioners have long been wary of potential problems there. And yet, with serious recent developments potentially impacting trade and on-the-ground operations, now is a good time to reassess China compliance risks.… Continue Reading
GlaxoSmithKline said in a securities filing Wednesday that the DOJ and SEC asked for information about third-party advisers the company hired in China during a corruption investigation there.
GSK said it is also responding to requests from the SFO for more information about the third parties.… Continue Reading
A federal judge in Philadelphia Friday dismissed a civil complaint against UK-based GlaxoSmithKline brought by a British private investigator and his American wife and their China-based company.
Peter Humphrey and Yu Yingzeng, his wife and business partner, sued GSK a year ago.… Continue Reading
Pharmaceuticals companies continue to fall foul of the FCPA and other anti-bribery laws, with a number of 2016 cases suggesting a vulnerability around marketing practices especially in the Asia-Pacific region. Why does a sector that is way ahead of the compliance game in so many ways keep getting caught out by anti-bribery laws?… Continue Reading
What does the failure of the Kraft Heinz attempted hostile takeover of Unilever portend for the greater world of global anti-corruption enforcement specifically and compliance programs more generally?
As with most business issues during the new administration, things are in flux.… Continue Reading
The Securities and Exchange Commission said Friday UK-based pharma GlaxoSmithKline plc will pay a $20 million civil penalty to settle charges that it violated the Foreign Corrupt Practices Act when China-based subsidiaries spent millions of dollars on pay-to-prescribe schemes for several years to pump up sales.… Continue Reading
At Pinsent Masons regulatory conference in London a few weeks ago, David Green, the chief of the UK Serious Fraud Office, talked about how many known frauds happen on his turf.… Continue Reading
In my prior post on Collective Action, I wrote about the importance of voluntary codes of conduct and concluded that in an era of weak regulation, corporate behaviour would have been significantly worse over the last decades without them.… Continue Reading
Job Title: Regional Specialist, Anti-Bribery & Corruption
The ABAC Regional Specialists will understand their local market needs AND global ABAC issues to be able to feed information back to the ABAC Programme.… Continue Reading